Oncotarget

Research Papers:

Clinical validation of the Tempus xO assay

Nike Beaubier _, Robert Tell, Robert Huether, Martin Bontrager, Stephen Bush, Jerod Parsons, Kaanan Shah, Tim Baker, Gene Selkov, Tim Taxter, Amber Thomas, Sam Bettis, Aly Khan, Denise Lau, Christina Lee, Matthew Barber, Marcin Cieslik, Casey Frankenberger, Amy Franzen, Ali Weiner, Gary Palmer, Robert Lonigro, Dan Robinson, Yi-Mi Wu, Xuhong Cao, Eric Lefkofsky, Arul Chinnaiyan and Kevin P. White

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:25826-25832. https://doi.org/10.18632/oncotarget.25381

Metrics: PDF 549 views  |   HTML 986 views  |   ?  


Abstract

Nike Beaubier1, Robert Tell1, Robert Huether1, Martin Bontrager1, Stephen Bush1, Jerod Parsons1, Kaanan Shah1, Tim Baker1, Gene Selkov1, Tim Taxter1, Amber Thomas1, Sam Bettis1, Aly Khan1, Denise Lau1, Christina Lee1, Matthew Barber1, Marcin Cieslik2, Casey Frankenberger1, Amy Franzen1, Ali Weiner1, Gary Palmer1, Robert Lonigro2, Dan Robinson2, Yi-Mi Wu2, Xuhong Cao2, Eric Lefkofsky1, Arul Chinnaiyan2,3 and Kevin P. White1

1Tempus Labs, Inc., Chicago, Illinois 60654, USA

2Department of Pathology and Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan 48109, USA

3Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA

Correspondence to:

Nike Beaubier, email: nike.beaubier@tempus.com

Kevin P. White, email: kevin@tempus.com

Keywords: genomic test; gene panel; cancer; transcriptome; Tempus

Received: August 20, 2017    Accepted: March 21, 2018    Published: May 25, 2018

ABSTRACT

We have developed a clinically validated NGS assay that includes tumor, germline and RNA sequencing. We apply this assay to clinical specimens and cell lines, and we demonstrate a clinical sensitivity of 98.4% and positive predictive value of 100% for the clinically actionable variants measured by the assay. We also demonstrate highly accurate copy number measurements and gene rearrangement identification.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25381